Issue 1, 2017

A Cu(ii) complex targeting the translocator protein: in vitro and in vivo antitumor potential and mechanistic insights

Abstract

A new Cu-based anticancer metallodrug which targets the translocator protein is reported. [CuBr2(TZ6)] elicits a remarkable in vitro cytotoxicity in sensitive and multidrug resistant cell lines and induces a 98% reduction of tumor mass in a murine tumor model. Target binding was studied by experimental and computational methods.

Graphical abstract: A Cu(ii) complex targeting the translocator protein: in vitro and in vivo antitumor potential and mechanistic insights

Supplementary files

Article information

Article type
Communication
Submitted
07 Oct 2016
Accepted
01 Dec 2016
First published
01 Dec 2016

Chem. Commun., 2017,53, 134-137

A Cu(II) complex targeting the translocator protein: in vitro and in vivo antitumor potential and mechanistic insights

D. Montagner, B. Fresch, K. Browne, V. Gandin and A. Erxleben, Chem. Commun., 2017, 53, 134 DOI: 10.1039/C6CC08100B

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements